Current research projects
Clinical Trials
Glomerulopathies
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (I CAN)
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (I CAN)
- AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
- A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
- A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
- Phase 3, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in subjects with immunoglobulin A nephropathy
- Metformin versus Tolvaptan in adults with Autosomal Dominant Plycystic Kidney Disease: a phase 3a, indipendent, multi-centre, 2 parallel arms randomized-controlled trial
- Sperimentazione di fase 3, multicentrica, randomizzata, in doppio cieco, controllata con placebo per valutare l’efficacia e la sicurezza di sibeprenlimab somministrato per via sottocutanea in soggetti con nefropatia da immunoglobulina A
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS, INCLUDING AN EVALUATION OF OPEN LABEL SA
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomeruloscle
- Phase 3, randomized, double-blind, active versus control cycle to evaluate the safety and efficacy of CCX168 (Avacopan) in patients with cytoplasmic antineutrophil associated vasculitis (ANCA) in combination with rituximab ofosfamide / azathioprine.
- A Phase 3, Randomized, Double-blinded, Placebo-controlled, multicenter study to evaluate the efficacy and safety of Pegcetacoplan in patients with primary C3 glomerulopathy or Immuno-Complex Membranoproliferative Glomerulonephritis
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
- A PHASE III, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS EUDRACT
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)
- A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
- Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)
- A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy
- A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)
- A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
- Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).
- Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Obinutuzumab in patients with class III or IV lupus nephritis according to ISN / RPS 2003 criteria
- Treatment of IGA nEphropathy according to Renal lesions (TIGER)
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY- 021IGAN17001
- OL Extension Study of LNP023 in C3G
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVECONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
- AN EXTENDED ACCESS PROGRAM TO ASSESS LONG TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE (EAGLE)
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
- LEARNS: Levamisole as Adjuvant therapy to Reduce relapses of Nephrotic Syndrome
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)
- PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN(RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITHFOCALSEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY
- Genetic, genomic, and biomarker studies of Henoch-Schönlein purpura and IgA nephropathy in kids
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
CKD and Dialysis in Children
- A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic
- A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
- Development, validation and clinical reliability of a predictive machine learning model for volume management in pediatric intensive care unit
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Pediatric Kidney Transplantation
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and The
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s PED-HZ/su in paediatric renal transplant recipients (GSK , UK)
- A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocomprom
- A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocomprom
Cohort Studies and Registries
Glomerulopathies
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
CKD and Dialysis in Children
Pediatric Kidney Transplantation
Translational Research Projects
Glomerulopathies
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
CKD and Dialysis in Children
Pediatric Kidney Transplantation
